Professor In Residence, Helen Diller Family Comprehensive Cancer Center and Department of Anatomy, UCSF; Director, Preclinical Therapeutics Core Facility, Helen Diller Family Comprehensive Cancer Center, UCSF
Additional Websites
Education
Imperial College of Science and Technology, University of London, UK, BSc (Hons), 1st class, 1975-1978, Biochemistry
Beatson Institute for Cancer Research, Glasgow, UK, PhD, 1978-1981, Molecular Biology
Professional Experience
-
1982-1984
Post-doctoral fellow, California Institute of Technology, Pasadena, CA
-
1984-1988
Lecturer, Department of Biochemistry and Molecular Genetics, St. Mary's Hospital Medical School, London University, UK
-
1988-1990
Lecturer, Department of Medical Genetics, Glasgow University, UK
-
1990-1992
Senior Lecturer, Department of Medical Genetics, Glasgow University, UK
-
1992-1996
Reader, Department of Medical Genetics, Glasgow University, UK
-
1997-1999
Senior Scientist, Onyx Pharmaceuticals, Richmond, CA
-
1999-2004
Research Scientist, Cancer Research Institute, UCSF
-
2004-2007
Adjunct Professor, Dept of Anatomy and Cancer Research Institute, UCSF
-
2007-present
Professor In Residence, Dept of Anatomy and Cancer Research Institute, UCSF
Honors & Awards
- 1975, 1976
Imperial College Entrance Scholarship - 1978
Ewart Stickings Award for Excellence in Biochemistry (Top Biochemistry Student, Imperial College, London) - 1978
Associate of the Royal College of Science - 1982-4
European Molecular Biology Organization (EMBO) Fellowship Award - 1984
"New Blood" Lectureship, London University, UK - 2011-2017
Charter Member NIH VCMB Study Section
Selected Publications
- Kang HC, Quigley D, Kim IJ, Wakabayashi Y, Ferguson-Smith MA, D'Alessandro M, Lane EB, Akhurst RJ, Goudie DR, Balmain A. Multiple Self-Healing Squamous Epithelioma (MSSE): Rare Variants in an Adjacent Region of Chromosome 9q22.3 to known TGFBR1 Mutations Suggest a Digenic or Multilocus Etiology. J Invest Dermatol. 2013 Jan 28.
View on PubMed - Freimuth J, Clermont FF, Huang X, Desapio A, Tokuyasu TA, Sheppard D, Akhurst RJ. Epistatic interactions between Tgfb1 and genetic loci, Tgfbm2 and Tgfbm3, determine susceptibility to an asthmatic stimulus. Proc Natl Acad Sci U S A. 2012 Oct 30; 109(44):18042-7.
View on PubMed - Akhurst RJ, Hata A. Targeting the TGFß signalling pathway in disease. Nat Rev Drug Discov. 2012 Oct; 11(10):790-811.
View on PubMed - Akhurst RJ. The paradoxical TGF-ß vasculopathies. Nat Genet. 2012 Aug; 44(8):838-9.
View on PubMed - Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-ß targeted cancer therapy. Int J Biol Sci. 2012; 8(7):964-78.
View on PubMed - Lamouille S, Connolly E, Smyth JW, Akhurst RJ, Derynck R. TGF-ß-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci. 2012 Mar 1; 125(Pt 5):1259-73.
View on PubMed - Arnold TD, Ferrero GM, Qiu H, Phan IT, Akhurst RJ, Huang EJ, Reichardt LF. Defective retinal vascular endothelial cell development as a consequence of impaired integrin aVß8-mediated activation of transforming growth factor-ß. J Neurosci. 2012 Jan 25; 32(4):1197-206.
View on PubMed - Benzinou M, Clermont FF, Letteboer TG, Kim JH, Espejel S, Harradine KA, Arbelaez J, Luu MT, Roy R, Quigley D, Higgins MN, Zaid M, Aouizerat BE, van Amstel JK, Giraud S, Dupuis-Girod S, Lesca G, Plauchu H, Hughes CC, Westermann CJ, Akhurst RJ. Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nat Commun. 2012; 3:616.
View on PubMed - Connolly EC, Akhurst RJ. The complexities of TGF-ß action during mammary and squamous cell carcinogenesis. Curr Pharm Biotechnol. 2011 Dec; 12(12):2138-49.
View on PubMed - Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC, Barcellos-Hoff MH. TGFß1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res. 2011 Nov 1; 17(21):6754-65.
View on PubMed - Connolly EC, Saunier EF, Quigley D, Luu MT, De Sapio A, Hann B, Yingling JM, Akhurst RJ. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TßRI/II kinase inhibition with LY2109761. Cancer Res. 2011 Mar 15; 71(6):2339-49.
View on PubMed - Akhurst RJ. Taking thalidomide out of rehab. Nat Med. 2010 Apr; 16(4):370-2.
View on PubMed - Harradine KA, Ridd K, Saunier EF, Clermont FF, Perez-Losada J, Moore DH, Epstein EH, Bastian BC, Akhurst RJ. Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. Clin Cancer Res. 2009 Aug 15; 15(16):5101-7.
View on PubMed - Barcellos-Hoff MH, Akhurst RJ. Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res. 2009; 11(1):202.
View on PubMed - Kang JS, Saunier EF, Akhurst RJ, Derynck R. The type I TGF-beta receptor is covalently modified and regulated by sumoylation. Nat Cell Biol. 2008 Jun; 10(6):654-64.
View on PubMed - Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol. 2007 Sep; 9(9):1000-4.
View on PubMed - Saunier EF, Akhurst RJ. TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets. 2006 Nov; 6(7):565-78.
View on PubMed - Akhurst RJ. Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr Opin Investig Drugs. 2006 Jun; 7(6):513-21.
View on PubMed - Mao JH, Saunier EF, de Koning JP, McKinnon MM, Higgins MN, Nicklas K, Yang HT, Balmain A, Akhurst RJ. Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility. Proc Natl Acad Sci U S A. 2006 May 23; 103(21):8125-30.
View on PubMed - Akhurst RJ. A sweet link between TGFbeta and vascular disease? Nat Genet. 2006 Apr; 38(4):400-1.
View on PubMed
View on UCSF Profiles
